Neuropathic Pain Therapy: From Bench to Bedside

被引:21
作者
Backonja, Miroslav 'Misha' [1 ,2 ]
机构
[1] CRILifetree, Neurosci Clin Res, Salt Lake City, UT USA
[2] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA
关键词
neuropathic pain; somatosensory nervous system; mechanisms of action; analgesia; POSTHERPETIC NEURALGIA; GENERAL-POPULATION; DOUBLE-BLIND; MECHANISMS; POLYNEUROPATHY; GUIDELINES; NGX-4010; PATCH;
D O I
10.1055/s-0032-1329204
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuropathic pain is a result of complex interactions between peripheral and central mechanisms with multiple potential therapeutic targets. However, the complexity of these mechanisms and relative youth of translational pain research, which is in its infancy, have prevented translation of successful basic bench research to human therapy. Most of the clinically available neuropathic pain treatments are borrowed from other therapeutic areas, such as antidepressants and antiepileptics, or involve application of older therapy, such as opioids. Exceptions are ziconotide, tapentadol, and the high-concentration capsaicin patch. Similar to all other analgesic agents, these provide only partial pain relief in subsets of patients. The standard of care for patients with chronic neuropathic pain is multimodal and multidisciplinary. For most patients to achieve and maintain satisfactory pain relief a combination of therapeutic agents is necessary, providing the empiric basis for rational polypharmacy, which has become a standard approach as well.
引用
收藏
页码:264 / 268
页数:5
相关论文
共 35 条
[1]   Human brain mechanisms of pain perception and regulation in health and disease [J].
Apkarian, AV ;
Bushnell, MC ;
Treede, RD ;
Zubieta, JK .
EUROPEAN JOURNAL OF PAIN, 2005, 9 (04) :463-484
[2]   Consensus guidelines: Treatment planning and options [J].
Argoff, CE ;
Backonja, MM ;
Belgrade, MJ ;
Bennett, GJ ;
Clark, MR ;
Cole, BE ;
Fishbain, DA ;
Irving, GA ;
McCarberg, BH ;
McLean, MJ .
MAYO CLINIC PROCEEDINGS, 2006, 81 (04) :S12-S25
[3]  
Backonja M M., 2005, Journal of Neuropathic Pain Symptom Palliation, V1, P11, DOI DOI 10.3109/J426V01N02_03
[4]   NGX-4010, a high concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study (vol 7, pg 1106, 2008) [J].
Backonja, M. ;
Wallace, M. S. ;
Blonsky, E. R. .
LANCET NEUROLOGY, 2009, 8 (01) :31-31
[5]   Rational multidrug therapy in the treatment of neuropathic pain [J].
Backonja M.-M. ;
Irving G. ;
Argoff C. .
Current Pain and Headache Reports, 2006, 10 (1) :34-38
[6]   Pain assessment and evaluation of patients who have neuropathic pain [J].
Backonja, MM ;
Galer, BS .
NEUROLOGIC CLINICS, 1998, 16 (04) :775-+
[7]  
Baron Ralf, 2009, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-540-79090-7_1
[8]   Using screening tools to identify neuropathic pain [J].
Bennett, Michael I. ;
Attal, Nadine ;
Backonja, Miroslav M. ;
Baron, Ralf ;
Bouhassira, Didier ;
Freynhagen, Rainer ;
Scholz, Joachim ;
Toelle, Thomas R. ;
Wittchen, Hans-Ulrich ;
Jensen, Troels Staehelin .
PAIN, 2007, 127 (03) :199-203
[9]   Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies [J].
Bley, KR .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (11) :1445-1456
[10]   Development and validation of the neuropathic pain symptom inventory [J].
Bouhassira, D ;
Attal, N ;
Fermanian, J ;
Alchaar, H ;
Gautron, M ;
Masquelier, E ;
Rostaing, S ;
Lanteri-Minet, M ;
Collin, E ;
Grisart, J ;
Boureau, F .
PAIN, 2004, 108 (03) :248-257